SEATTLE, Jan. 21 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that management will present at the Piper Jaffray 17th Annual Healthcare Conference in New York on Thursday, January 27, 2005 at 3:00 pm EST, 12:00 pm PST. A live webcast of the presentation can be accessed by visiting Dendreon's website http://www.dendreon.com/ under the "Investor/Webcasts & Presentations" section or http://www.piperjaffray.com/hcwebcast. A replay of the presentation will be available for 30 days after the conference.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit http://www.dendreon.com/.
NOTE: Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov/.
CONTACT: Monique M. Greer, Sr. Director, Corporate Communications ofDendreon Corporation, +1-206-829-1500